<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52206">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426541</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00025</org_study_id>
    <secondary_id>2014-005377-36</secondary_id>
    <nct_id>NCT02426541</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>DERISC</acronym>
  <official_title>An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Antaros Medical AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioventure Hub</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>43183 Mölndal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week, single centre, randomized, parallel-group, double-blind,
      placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific
      insulin sensitivity in patients with Type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skeletal muscle insulin stimulated glucose uptake (µmol/min/kg) from baseline to end of treatment.</measure>
    <time_frame>From baseline to 8 weeks.</time_frame>
    <description>To evaluate if dapagliflozin 10 mg once daily when compared to placebo improves insulin sensitivity in skeletal muscle after 8 weeks of treatment in type 2 diabetes patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in adipose tissue insulin stimulated glucose uptake (µmol/min/kg) from baseline to end of treatment.</measure>
    <time_frame>From baseline to 8 weeks.</time_frame>
    <description>To evaluate if dapagliflozin 10 mg once daily when compared to placebo improves insulin sensitivity in adipose tissue after 8 weeks of treatment in type 2 diabetes patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver insulin stimulated glucose uptake (µmol/min/kg) from baseline to end of treatment.</measure>
    <time_frame>From baseline to 8 weeks.</time_frame>
    <description>To evaluate if dapagliflozin 10 mg once daily when compared to placebo improves insulin sensitivity in liver after 8 weeks of treatment in type 2 diabetes patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety by assessment of adverse events (AEs), serious adverse events (SAEs), vital signs, physical examination and clinical chemistry parameters.</measure>
    <time_frame>From baseline to 8 weeks.</time_frame>
    <description>To evaluate the safety of dapagliflozin 10 mg once daily in type 2 diabetes patients.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin Once Daily 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for Dapagliflozin Once Daily 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga, Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Provision of signed informed consent prior to any study specific procedures.

          2. Female or male aged 35 to 70 years inclusive with suitable veins for cannulation or
             repeated venipuncture

          3. Type 2 Diabetes mellitus defined as HbA1c of ≥ 6.5% and ≤ 10.5%.

          4. Stable (≥ 3 months) T2D treatment with metformin and/or metformin+dipeptidyl
             peptidase-4 inhibitors (DPP-IV)

          5. Body mass index (BMI) ≤ 40 kg/m2.

          6. Female subjects must be of non-childbearing potential, meeting at least one of the
             following criteria:

               1. Hysterectomized females

               2. Postmenopausal women, defined as women who have not had a menstrual period
                  within 1 year

        Main Exclusion Criteria:

          1. Any condition that is contraindicated with MRI such as, but not limited to, having a
             pacemaker or claustrophobia.

          2. Volume depleted patients. Patients at risk for volume depletion due to co-existing
             conditions or concomitant medications, such as loop diuretics should have careful
             monitoring of their volume status.

          3. Recent Cardiovascular Events in a patient:

               -  Acute Coronary Syndrome (ACS) within 2 months prior to enrolment

               -  Hospitalization for unstable angina or acute myocardial infarction within 2
                  months prior to enrolment

               -  Acute Stroke or Transient Ischemic Attack (TIA) within two months prior to
                  enrolment

               -  Less than two months post coronary artery revascularization

          4. Congestive heart failure defined as New York Heart Association (NYHA) class IV,
             unstable or acute congestive heart failure.

          5. Blood pressure at enrolment: Systolic BP ≥165 mm Hg and/or diastolic BP ≥100 mm Hg

          6. Any clinically significant illness, medical or surgical procedure or trauma within 4
             weeks of the first administration of the investigational product.

          7. On insulin, GLP-1 or other oral antidiabetic drug treatment (metformin or both
             metformin and DPP-IV allowed) or using other medications known to affect glucose
             metabolism.

          8. Any clinically significant abnormalities in physical examination, Electrocardiography
             (ECG) or clinical chemistry results as judged by the investigator. The following
             specific exclusion criteria apply to the selected Clinical Chemistry results:

               1. Creatinine clearance &lt;60mL/min (estimated with Cockroft-Gault formula).

               2. Severe hepatic insufficiency and/or significant abnormal liver function defined
                  as aspartate aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or
                  alanine aminotransferase (ALT) &gt;3x ULN.

               3. Total bilirubin (TB) &gt;2.0 mg/dL (34.2 µmol/L).

          9. Body weight loss greater than 5% within 3 months prior to Visit 1.

         10. Previous PET scan

         11. History of or presence of (as found at Visit 1) any clinically significant disease,
             disorder or condition which, in the opinion of the investigator, may either put the
             subject at risk because of participation in the study, or influence the results or
             the subject's ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirjo Nuutila, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku PET Centre, Turku, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 11, 2016</lastchanged_date>
  <firstreceived_date>April 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Dapagliflozin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
